Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): Study Protocol for a Phase I Trial Treating Polymetastatic Cancer with Stereotactic Radiotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Apr 15

PMID 33853550

Citations 16

Authors

Glenn S Bauman

Mark T Corkum

Hatim Fakir

Timothy K Nguyen

David A Palma

Affiliations

Soon will be listed here.

Abstract

Background: Patients with polymetastatic cancer are most often treated with systemic therapy to improve overall survival and/or delay progression, with palliative radiotherapy reserved for sites of symptomatic disease. Stereotactic ablative radiotherapy (SABR) has shown promise in the treatment of oligometastatic disease, but the utility of SABR in treating all sites of polymetastatic disease has yet to be evaluated. This study aims to evaluate the maximally tolerated dose (MTD) of SABR in patients with polymetastatic disease.

Methods: Up to 48 patients with polymetastatic cancer (> 10 sites) will be enrolled on this phase I, modified 3 + 3 design trial. Eligible patients will have exhausted (or refused) standard systemic therapy options. SABR will be delivered as an escalating number of weekly fractions of 6 Gy, starting at 6 Gy × 2 weekly fractions (dose level 1). The highest dose level (dose level 4) will be 6 Gy × 5 weekly fractions. Feasibility and safety of SABR will be evaluated 6 weeks following treatment using a composite endpoint of successfully completing treatment as well as toxicity outcomes.

Discussion: This study will be the first to explore delivering SABR in patients with polymetastatic disease. SABR will be planned using the guiding principles of: strict adherence to dose constraints, minimization of treatment burden, and minimization of toxicity. As this represents a novel use of radiotherapy, our phase I study will allow for careful selection of the MTD for exploration in future studies.

Trial Registration: This trial was prospectively registered in ClinicalTrials.gov as NCT04530513 on August 28, 2020.

Citing Articles

Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma.

Ezzat S, Pasternak J, Rajaraman M, Abdel-Rahman O, Boucher A, Chau N Front Oncol. 2024; 14:1437360.

PMID: 39558957 PMC: 11570806. DOI: 10.3389/fonc.2024.1437360.

Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.

Sherry A, Lin T, McCaw Z, Beck E, Kouzy R, Abi Jaoude J Int J Radiat Oncol Biol Phys. 2024; 120(5):1239-1244.

PMID: 39352322 PMC: 11586112. DOI: 10.1016/j.ijrobp.2024.05.033.

Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?.

Lancia A, Ingrosso G, Detti B, Festa E, Bonzano E, Linguanti F Front Oncol. 2024; 14:1455428.

PMID: 39314633 PMC: 11417306. DOI: 10.3389/fonc.2024.1455428.

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol.

Palma D, Giuliani M, Correa R, Schneiders F, Harrow S, Guckenberger M BMC Palliat Care. 2024; 23(1):223.

PMID: 39244532 PMC: 11380777. DOI: 10.1186/s12904-024-01548-7.

Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.

Cao Y, Sutera P, Mendes W, Yousefi B, Hrinivich T, Deek M Radiother Oncol. 2024; 199:110443.

PMID: 39094629 PMC: 11405100. DOI: 10.1016/j.radonc.2024.110443.

References

Palma D, Salama J, Lo S, Senan S, Treasure T, Govindan R . The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014; 11(9):549-57. DOI: 10.1038/nrclinonc.2014.96. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

Corkum M, Rodrigues G . Patient selection for thoracic radiotherapy in extensive-stage small-cell lung cancer. Lung Cancer Manag. 2019; 6(2):47-53. PMC: 6310308. DOI: 10.2217/lmt-2017-0006. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Bauman G, Charette M, Reid R, Sathya J . Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol. 2005; 75(3):258-70. DOI: 10.1016/j.radonc.2005.03.003. View

Hellman S, Weichselbaum R . Oligometastases. J Clin Oncol. 1995; 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. View

Palma D, Bauman G, Rodrigues G . Beyond Oligometastases. Int J Radiat Oncol Biol Phys. 2020; 107(2):253-256. DOI: 10.1016/j.ijrobp.2019.12.023. View

Kennedy T, Corkum M, Louie A . Stereotactic radiotherapy in oligometastatic cancer. Chin Clin Oncol. 2017; 6(Suppl 2):S16. DOI: 10.21037/cco.2017.06.20. View

Paluri R, Li P, Anderson A, Nandagopal L, McArdle T, Young M . First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics. Sci Rep. 2020; 10(1):7935. PMC: 7220914. DOI: 10.1038/s41598-020-64906-4. View

10.

Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich S . Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2016; 7(1):4-12. DOI: 10.1016/j.prro.2016.08.001. View

11.

Ritter T, Matuszak M, Chetty I, Mayo C, Wu J, Iyengar P . Application of Critical Volume-Dose Constraints for Stereotactic Body Radiation Therapy in NRG Radiation Therapy Trials. Int J Radiat Oncol Biol Phys. 2017; 98(1):34-36. PMC: 5754194. DOI: 10.1016/j.ijrobp.2017.01.204. View

12.

Ruers T, Van Coevorden F, Punt C, Pierie J, Borel-Rinkes I, Ledermann J . Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017; 109(9). PMC: 5408999. DOI: 10.1093/jnci/djx015. View

13.

Palma D, Olson R, Harrow S, Correa R, Schneiders F, Haasbeek C . Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019; 19(1):816. PMC: 6699121. DOI: 10.1186/s12885-019-5977-6. View

14.

Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G . Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010; 16(1):3-10. DOI: 10.2174/138161210789941847. View

15.

Al-Shafa F, Arifin A, Rodrigues G, Palma D, Louie A . A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?. Front Oncol. 2019; 9:543. PMC: 6598429. DOI: 10.3389/fonc.2019.00543. View

16.

Parker C, James N, Brawley C, Clarke N, Hoyle A, Ali A . Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018; 392(10162):2353-2366. PMC: 6269599. DOI: 10.1016/S0140-6736(18)32486-3. View

17.

Salazar O, DaMotta N, Bridgman S, Cardiges N, Slawson R . Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose. Int J Radiat Oncol Biol Phys. 1996; 36(1):49-60. DOI: 10.1016/s0360-3016(96)00248-9. View

18.

Murrell D, Karnas S, Corkum M, Hipwell S, Palma D, Rodrigues G . Radical radiotherapy for locally advanced non-small cell lung cancer-what's up with arm positioning?. J Thorac Dis. 2019; 11(5):2099-2104. PMC: 6588765. DOI: 10.21037/jtd.2019.05.40. View

19.

Iyengar P, Wardak Z, Gerber D, Tumati V, Ahn C, Hughes R . Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2017; 4(1):e173501. PMC: 5833648. DOI: 10.1001/jamaoncol.2017.3501. View

20.

James S, Bednarz B, Benedict S, Buchsbaum J, Dewaraja Y, Frey E . Current Status of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2020; 109(4):891-901. PMC: 8422258. DOI: 10.1016/j.ijrobp.2020.08.035. View